Maternal-Fetal Drug Development: An Industry Perspective.

Area of Science:

• Pharmacology
• Obstetrics
• Regulatory Science

Background:

• Pregnant and lactating women are often excluded from clinical trials, leading to limited safety and efficacy data for medications used in this population.
• Regulatory agencies have issued guidance to encourage drug development for pregnant women, yet significant challenges remain.

Purpose of the Study:

• To provide an industry perspective on maternal-fetal drug development.
• To review the regulatory landscape, trial designs, and challenges in developing medications for pregnant women and their fetuses.
• To propose strategies for future drug and vaccine development in this population.

Main Methods:

• Review of regulatory guidance documents for maternal-fetal drug development.
• Analysis of clinical trial designs incorporating pregnant women.
• Identification of gaps and challenges in current drug development processes.

Main Results:

• Despite regulatory efforts, significant clinical, ethical, and developmental hurdles persist in maternal-fetal drug development.
• Innovative trial designs are essential to include pregnant women and their fetuses in studies.
• Limited data necessitates cautious prescribing of medications during pregnancy.

Conclusions:

• Optimizing the development of safe and effective medicines and vaccines for pregnant women requires early and continuous dialogue among all stakeholders.
• Addressing the unique needs of pregnant women in drug development is critical.
• Future strategies should focus on innovative trial designs and collaborative approaches.